Summary
Multiple drug administration may affect the actions of digoxin either by altering its myocardial effects (dose-response relationship or pharmacodynamic effect) or by altering the absorption, storage or excretion of the drug (a pharmacokinetic effect). The major pharmacodynamic interactions include potentiation of digitalis toxicity by potassium-wasting diuretics and by succinlycholine. β-Blocking drugs also increase the potential for digoxin to produce adverse sinus or A-V node dysfunction. The pharmacokinetic interactions can be divided into drug interactions which alter digoxin absorption and those which change renal excretion. Estimates of the former are usually based on either steady-state or single dose studies of bioavailability. These studies have demonstrated significant reduction of absorption of oral digoxin by simultaneously administered liquid antacids, cholestyramine, kaolin-pectin, and meals of high fibre content. Reduced digoxin absorption also occurs secondary to therapy with sulphasalazine, para-aminosalicylic acid, and neomycin, probably due to their effect upon gut wall function. Propantheline and diphenoxylate with atropine, which decrease gut motility, increase digoxin absorption, whereas metoclopramide, which increases motility, depresses absorption. The renal excretion of digoxin is not changed importantly by diuretics such as frusemide but is decreased by spironolactone, possibly due to inhibition of renal tubular secretion of digoxin.
Quinidine produces dramatic persistent increases in digoxin serum levels, due to decreased renal clearance of the glycoside, without changing the glomerular filtration. In addition to this renal effect, quinidine also seems to decrease the volume of distribution of digoxin, which results in acutely altered digoxin levels even within the first day after quinidine administration.
Alteration of the timing of the administration of digoxin from that of a second drug (e.g. as with liquid antacids, kaolin-pectin, or meals of high fibre content), or alteration of the dose of digoxin based on the anticipated change in kinetics (as with spironolactone, quinidine or medications altering gut function or motility), can improve clinical effectiveness of digoxin therapy. However, because of individual variation in the impact of these interactions, routine monitoring of digoxin serum levels is strongly recommended under such circumstances to enhance clinical efficacy and patient safety.
Similar content being viewed by others
References
Albert, K.S.; Ayres, J.W.; DiSanto, A.R.; Weidler, D.J.; Sakmar, E.; Hallmark, M.R.; Stoll, R.G.; DeSante, K.A. and Wagner, J.G.: Influence of kaolin-pectin suspension on digoxin bioavailability. Journal of Pharmaceutical Sciences 1: 1582–1586(1978).
Beermann, B.; Hellstrom, K. and Rosen, A.: The absorption of orally administered [12α-3H] digoxin in man. Clinical Science 43: 507–518(1972).
Beermann, B.; Hellstrom, K. and Rosen, A.: The gastrointestinal absorption of digoxin in seven patients with gastric or small intestinal reconstructions. Acta Medica Scandinavica 193: 293–297(1973).
Binnion, P.F.: The absorption of digoxin tablets. Clinical Pharmacology and Therapeutics 16: 807–812 (1974).
Binnion, P.F.: Drug interactions with digitalis glycosides. Drugs 15: 369–380(1978).
Bissett, J.K.; Doherty, J.E.; Flanigan, W.J.; Dalrymple, G.V.: Tritiated digoxin XIX. Turnover studies in diabetes insipidus. American Journal of Cardiology 31: 327–330 (1973).
Brown, D.D. and Abraham, G.N.: Plasma digoxin levels in normal human volunteers following chronic oral and intramuscular administration. Journal of Laboratory and Clinical Medicine 82: 201–207(1973).
Brown, D.D. and Juhl, R.P.: Decreased bioavailability of digoxin due to antacids and kaolin-pectin. New England Journal of Medicine 295: 1034–1037(1976).
Brown, D.D. and Juhl, R.P.: Altered bioavailability of digoxin produced by gastrointestinal medications. Clinical Research 27: 610A (1979).
Brown, D.D.; Dormois, J.C. and Abraham, G.N.: Effect of furosemide on the renal excretion of digoxin. Clinical Pharmacology and Therapeutics 20: 395–400 (1976).
Brown, D.D.; Juhl, R.P. and Warner, S.L.: Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Circulation 58: 164–172 (1978).
Caldwell, J.H.; Martin, J.F.; Dutta, S. and Greenberger, N.J.: Intestinal absorption of digoxin-3H in the rat. American Journal of Physiology 217: 1747–1751 (1969).
Doherty, j.E.; Ferrell, C.B. and Towbin, E.J.: Localization of the renal excretion of the tritiated digoxin. American Journal of the Medical Sciences 258: 181–189 (1969).
Doherty, J.E.; de Soyza, N.; Kane, J.J.; Bissen, J.K. and Murphy, M.L.: Clinical pharmacokinetics of digitalis glycosides. Progress in Cardiovascular Diseases 21: 141–158 (1978).
Doherty, J.E.; Flanigan, W.J. and Dalrymple, G.V.: Tritiated digoxin XVII. Excretion and turnover times in normal donors before and after nephrectomy and in the paired recipient of the kidney after transplantation. American Journal of Cardiology 29: 470–474(1972).
Doering, W.: Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications. New England Journal of Medicine 301: 400–404 (1979).
Doering, W. and Glumel, E.: Vereinfachte Serum-Digoxin-Bestimmung mit einem Jod-125-Solid-Phase-Test. Klinische Wochenschrift 56: 497–502 (1978).
Ejvinsson, G.: Effect of quinidine on plasma concentrations of digoxin. British Medical Journal 1: 279–280 (1978).
Greenblatt, D.J.; Duhme, D.W.; Koch-Weser, J. and Smith, T.W.: Evaluation of digoxin bioavailability in single-dose studies. New England Journal of Medicine 289: 651–653 (1973).
Greenblatt, D.J.; Duhme, D.W.; Koch-Weser, J. and Smith, T.W.: Bioavailability of digoxin tablets and elixir in the fasting and postprandial states. Clinical Pharmacology and Therapeutics 16: 444–448 (1974a).
Greenblatt, D.J.; Duhme, D.W.; Koch-Weser, J. and Smith, T.W.: Equivalent bioavailability from digoxin elixir and rapid-dissolution tablets. Journal of the American Medical Association 229: 1774–1776 (1974b).
Hager, W.D.; Fenster, P.; Mayersohn, M.; Perrier, D.; Graves, P.; Marcus, F.I. and Goldman, S.: Digoxin-quinidine interaction: Pharmacokinetic evaluation. New England Journal of Medicine 300: 1238–1241 (1979).
Hall, W.H. and Doherty, J.E.: Tritiated digoxin XVI: Gastric absorption. Digestive Diseases 16: 903–908 (1971).
Hansten, P.D.: Drug interactions. Fourth Edition, pp.192–199 (Lea and Febiger, Philadelphia 1979).
Jelliffe, R.W.: Effect of serum potassium level upon risk of digitalis toxicity. Annals of Internal Medicine 78: 821 (1973).
Johnson, B.F.; Greer, H.; McCrerie, J.; Bye, C. and Fowle, A.: Rate of dissolution of digoxin tablets as a predictor of absorption. Lancet 1: 1473–1475(1973).
Johnson, B.F.; Bye, C.; Jones, G. and Sabey, G.A.: A completely absorbed oral preparation of digoxin. Clinical Pharmacology and Therapeutics 19: 746–751 (1976).
Johnson, B.F.; O’Grady, J.; Sabey, G.A. and Bye, C.: Effect of a standard breakfast on digoxin absorption in normal subjects. Clinical Pharmacology and Therapeutics 23: 315–319 (1978).
Juhl, R.P.; Summers, R.W.; Guillory, J.K.; Blaug, S.M.; Cheng, F.H. and Brown, D.D.: Effect of sulfasalazine on digoxin bioavailability. Clinical Pharmacology and Therapeutics 20: 387–394(1976).
Khalil, S.A.H.: The uptake of digoxin and digitoxin by some antacids. Journal of Pharmacy and Pharmacology 26: 961–967 (1974).
Koch-Weser, J.: Bioavailability of drugs. New England Journal of Medicine 291: 233–237, 503-506 (1974).
Leahey, E.B.; Reiffel, J.A.; Drusin, R.E.; Heissenbuttel, R.H.; Lovejoy, W.P. and Bigger, J.T.: Interaction between quinidine and digoxin. Journal of the American Medical Association 240: 533–534(1978).
Leahey, E.B.; Reiffel, J.A.; Heissenbuttel, R.H.; Drusin, R.E.; Lovejoy, W.P. and Bigger, J.T.: Enhanced cardiac effect of digoxin during quinidine treatment. Archives of Internal Medicine 139: 519–521 (1979).
Lindenbaum, J.; Mellow, M.H.; Blackstone, M.O. and Butler, V.P. Jr.: Variation in biologic availability of digoxin from four preparations. New England Journal of Medicine 285: 1344–1347(1971).
Lindenbaum, J.; Butler, V.P. Jr.; Murphy, J.E. and Creswell, R.M.: Correlation of digoxin tablet dissolution-rate with biological availability. Lancet 1: 1215–1217(1973).
Lindenbaum, J.; Maulitz, R.M. and Butler, V.P. Jr.: Inhibition of digoxin absorption by neomycin. Gastroenterology 71: 399–404(1976).
Lloyd, B.L.; Greenblatt, D.J.; Allen, D.J.; Harmatz, J.S. and Smith, T.W.: Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses. American Journal of Cardiology 42: 129–136 (1978).
McAllister, R.G. Jr.; Howell, S.M.; Gomer, M.S. and Selby, J.B.: Effect of intravenous furosemide on the renal excretion of digoxin. Journal of Clinical Pharmacology 16: 110–117 (1976).
Mallis, G.I.; Schmidt, D.H. and Lindenbaum, J.: Superior bioavailability of digoxin solution in capsules. Clinical Pharmacology and Therapeutics 18: 761–768 (1975).
Manninen, V.; Melin, J.; Apajalahti, A. and Karesoja, M.: Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet 1: 398–400(1973).
Marcus, F.I.: Current status of therapy with digoxin. Current Problems in Cardiology 3: 1–41 (1978).
Marcus, F.I.; Dickerson, J.; Pippin, S.; Stafford, M.S. and Bressier, R.: Digoxin bioavailability: Formulations and rates of infusions. Clinical Pharmacology and Therapeutics 20: 253–259(1976).
Marcus, F.I.; Quinn, E.J.; Horton, H.; Jacobs, S.; Pippin, S.; Stafford, M. and Zukoski, C.: The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man. Circulation 55: 537–541 (1977).
Okada, R.D.; Hager, W.D.; Graves, P.E.; Mayersohn, M.; Perrier, D.G. and Marcus, F.I.: Relationship between plasma concentration and dose of digoxin in patients with and without renal impairment. Circulation 58: 1196–1203 (1978).
O’Malley, K.; Judge, T.G. and Crooks, J.: Geriatric Clinical Pharmacology and Therapeutics; in Avery, G.S. (Ed) Drug Treatment, pp. 168–171 (ADIS Press, Sydney and New York; Churchill Livingstone, Edinburgh 1980).
Preibisz, J.J.; Butler, V.P. Jr. and Lindenbaum, J.: Digoxin tablet bioavailability: Single-dose and steady-state assessment. Annals of Internal Medicine 81: 469–474 (1974).
Roman, R.J. and Kauker, M.L.: Renal tubular transport of 3H-digoxin in saline diuresis in rats: Evaluation by micropuncture. Circulation Research 38: 185–191 (1976).
Sloman, J.G. and Manolas, E.: Cardiovascular Diseases; in Avery, G.S. (Ed) Drug Treatment, pp.608–620 (ADIS Press, Sydney and New York; Churchill Livingstone, Edinburgh 1980).
Spector, R.: Digitalis therapy in heart failure: A rational approach. Journal of Clinical Pharmacology 19: 692–696 (1979).
Steiness, E.: Renal tubular secretion of digoxin. Circulation 50: 103–107(1974).
Waldorff, S.; Andersen, J.D.; Heebøll-Nielsen, N.; Nielsen, O.G.; Moltke, E.; Sørensen, U. and Steiness, E.: Spironolactone-induced changes in digoxin kinetics. Clinical Pharmacology and Therapeutics 24: 162–167 (1978).
Watt, D.A.L.: Sensitivity to propranolol after digoxin intoxication. British Medical Journal 3: 413–415 (1968).
Woods, M.N. and Ingelfinger, J.A.: Lack of effect of bran on digoxin absorption. Clinical Pharmacology and Therapeutics 26: 21–23(1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brown, D.D., Spector, R. & Juhl, R.P. Drug Interactions with Digoxin. Drugs 20, 198–206 (1980). https://doi.org/10.2165/00003495-198020030-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198020030-00003